Cell-Free Dna And Androgen Receptor Amplification Correlate With Clinical Outcomes In Castration-Resistant Prostate Cancer

You have accessJournal of UrologyProstate Cancer: Markers (MP60)1 Sep 2021MP60-19 CELL-FREE DNA AND ANDROGEN RECEPTOR AMPLIFICATION CORRELATE WITH CLINICAL OUTCOMES IN CASTRATION-RESISTANT PROSTATE CANCER Yuka Kubota, Shingo Hatakeyama, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, and Chikara Ohyama Yuka KubotaYuka Kubota More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Teppei OkamotoTeppei Okamoto More articles by this author , Hayato YamamotoHayato Yamamoto More articles by this author , Takahiro YoneyamaTakahiro Yoneyama More articles by this author , Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002095.19AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: To investigate the prognostic significance of total cell-free DNA (cfDNA) and androgen receptor amplification (AR -amp) in patients with castration-resistant prostate cancer (CRPC). METHODS: We retrospectively compared the total cfDNA and AR -amp levels in 42 individuals without prostate cancer, 57 patients with localized prostate cancer without androgen deprivation therapy (ADT), 97 patients with castration-sensitive prostate cancer (CSPC) with ADT, and 97 patients with CRPC. The association of these cfDNA biomarkers on disease status and overall survival was evaluated using Kaplan–Meier analysis and multivariable Cox regression analysis. Finally, a simple risk model was developed including total cfDNA and AR -amp to predict poor prognosis. RESULTS: The median total cfDNA and AR -amp levels in patients with CRPC was 387 pg/μL and 1.07 copies, respectively. The total cfDNA and AR -amp levels were significantly higher in the patients with CRPC than in individuals without prostate cancer, patients with localized prostate cancer without ADT, and patients with CSPC with ADT. Total cfDNA-high (>600 pg/μL) and AR -amp-high (>1.26 copies) were significantly associated with poor overall survival. Multivariable Cox regression analysis showed cfDNA-high and AR -amp -high were significantly associated with poor overall survival in patients with CRPC. We developed a risk model using cfDNA-high (score 1) and AR -amp-high (score 1). The risk score 1-2 was significantly associated with worse overall survival than score 0. CONCLUSIONS: Total cfDNA and AR -amp levels are potential biomarkers for poor prognosis in patients with CRPC. Source of Funding: The authors have no conflicts of interest associated with this manuscript. © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1049-e1049 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Yuka Kubota More articles by this author Shingo Hatakeyama More articles by this author Teppei Okamoto More articles by this author Hayato Yamamoto More articles by this author Takahiro Yoneyama More articles by this author Yasuhiro Hashimoto More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement Loading ...